Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
Hydroxamate-based histone deacetylase inhibitors (Hb-HDACIs), such as vorinostat, belinostat and panobinostat, have been previously shown to have a wide range of activity in hematologic malignancies such as cutaneous T-cell lymphoma and multiple myeloma. Recent data show that they synergize with a v...
Main Authors: | Marinella Zilli, Laura Iezzi, Felice Simiele, Antonino Grassadonia, Pasquale Cioffi, Clara Natoli |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2013-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | http://www.mdpi.com/2072-6694/5/3/919 |
Similar Items
-
Thiết kế, tổng hợp và đánh giá khả năng ức chế enzyme histone deacetylase (HDAC) in silico của một số dẫn xuất tương tự belinostat
by: Nguyễn Cường Quốc, et al.
Published: (2020-06-01) -
Histone deacetylase inhibition by suberoylanilide hydroxamic acid during reperfusion promotes multifaceted brain and vascular protection in spontaneously hypertensive rats with transient ischaemic stroke
by: Andrea Díaz-Pérez, et al.
Published: (2024-03-01) -
Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases
by: Anton Frühauf, et al.
Published: (2021-08-01) -
Experimental <it>in vivo</it> and <it>in vitro</it> treatment with a new histone deacetylase inhibitor belinostat inhibits the growth of pancreatic cancer
by: Dovzhanskiy Dmitriy I, et al.
Published: (2012-06-01) -
Quantitative Acetylomics Uncover Acetylation-Mediated Pathway Changes Following Histone Deacetylase Inhibition in Anaplastic Large Cell Lymphoma
by: Maša Zrimšek, et al.
Published: (2022-08-01)